State Street SPDR S&P Biotech ETF
816 hedge funds and large institutions have $16.7B invested in State Street SPDR S&P Biotech ETF in 2026 Q1 according to their latest regulatory filings, with 106 funds opening new positions, 251 increasing their positions, 241 reducing their positions, and 95 closing their positions.
19.27% more ownership
Funds ownership: 199.12% → 218.39% (+19%)
16% more funds holding in top 10
Funds holding in top 10: 19 → 22 (+3)
12% more first-time investments, than exits
New positions opened: 106 | Existing positions closed: 95
4% more repeat investments, than reductions
Existing positions increased: 251 | Existing positions reduced: 241
1% more capital invested
Capital invested by funds: $16.5B → $16.7B (+$235M)
0% more funds holding
Funds holding: 814 → 816 (+2)
54% less call options, than puts
Call options by funds: $2.19B | Put options by funds: $4.74B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$570M |
| 2 |
JP Morgan Chase
New York
|
+$370M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$212M |
| 4 |
Barclays
London,
United Kingdom
|
+$118M |
| 5 |
Morgan Stanley
New York
|
+$105M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$771M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$355M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$256M |
| 4 |
Citigroup
New York
|
-$233M |
| 5 |
Two Sigma Investments
New York
|
-$177M |
XBI Hedge Fund Activity: Q1 2026 in Review
816 of the 8,177 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q1 2026, worth a combined $16.7B — up 1.4% from $16.5B a quarter earlier.
Buyers outnumbered sellers: 106 funds opened new XBI positions and 95 closed out — a net gain of 11 holders — while 251 added to existing stakes and 241 trimmed.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $570M. The largest seller was Goldman Sachs, cutting an estimated $771M.
- 816 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q1 2026, up from 814 in Q4 2025.
- Funds reported $16.7B of State Street SPDR S&P Biotech ETF stock for Q1 2026, up 1.4% quarter-over-quarter.
- 106 funds opened new State Street SPDR S&P Biotech ETF positions in Q1 2026 and 95 closed out, a net change of +11 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q1 2026 was BNP Paribas Financial Markets, an estimated $570M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q1 2026 was Goldman Sachs, an estimated $771M sold.
Based on aggregated 13F filings for Q1 2026.